# Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer

> **NCT00115635** · PHASE1,PHASE2 · COMPLETED · sponsor: **Herlev Hospital** · enrollment: 60 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT00115635
- **Lead sponsor:** Herlev Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2007-10-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00115635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00115635, "Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00115635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*